ABSTRACT
Aims Type 2 diabetes (T2D) is a major risk factor for heart failure (HF) across demographic groups. On the other hand, metabolic impairment, including elevated T2D incidence is a hallmark of HF pathophysiology. We investigated the bidirectional relationship between T2D and HF, and identified genetic associations with diabetes-related HF after correction for potential collider bias.
Methods We performed a genome-wide association study (GWAS) of HF to identify genetic instrumental variables (GIVs) for HF, and to enable bidirectional Mendelian Randomization (MR) analysis between T2D and HF. Since genetics and HF can independently influence T2D, collider bias may occur when T2D (i.e., collider) is controlled for by design or analysis. Thus, we conducted GWAS of diabetes-related HF with correction for collider bias.
Results We first identified 61 genomic loci, including 24 novel loci, significantly associated with all-cause HF in 114,275 HF cases and over 1.5 million controls of European ancestry. Combined with the summary statistics of a T2D GWAS, we obtained 59 and 82 GIVs for HF and T2D, respectively. Using a two-sample bidirectional MR approach, we estimated that T2D increased HF risk (OR 1.07, 95% CI 1.04-1.10), while HF also increased T2D risk (OR 1.60, 95% CI 1.36-1.88). Then we performed a GWAS of diabetes-related HF corrected for collider bias due to prevalent HF affecting incidence of T2D. After removing the spurious association of TCF7L2 locus due to collider bias, we identified two genome-wide significant loci close to PITX2 (chromosome 4) and CDKN2B−AS1 (chromosome 9) associated with diabetes-related HF in the Million Veteran Program, and replicated the associations in the UK Biobank study.
Conclusion We identified novel HF-associated loci to enable bidirectional MR study of T2D and HF. Our MR findings support T2D as a HF risk factor and provide strong evidence that HF increases T2D risk. As a result, collider bias leads to spurious genetic associations of diabetes-related HF, which can be effectively corrected to identify true positive loci. Evaluation of collider bias should be a critical component when conducting GWAS of complex disease phenotypes such as diabetes-related cardiovascular complications.
Competing Interest Statement
Dr. Joseph reports research funding from Amgen, Kowa, Alnylam, Department of Veterans Affairs and National Institutes of Health. Within the past several years, Dr. Phillips has served on Scientific Advisory Boards for Boehringer Ingelheim and Janssen, and has or had research support from Merck, Pfizer, Eli Lilly, Novo Nordisk, Sanofi, PhaseBio, Roche, Abbvie, Vascular Pharmaceuticals, Janssen, Glaxo SmithKline, and the Cystic Fibrosis Foundation, and is also a cofounder, officer, board member and stockholder of a company, Diasyst, Inc., which markets software aimed to help improve diabetes management.
Funding Statement
This research is supported by funding from the Department of Veterans Affairs Office of Research and Development, Million Veteran Program Grant CX001737, BX005831, BX004821, and MVP065 (Joseph/Sun). This publication does not represent the views of the Department of Veterans Affairs or the United States Government. This research has also been supported in part by National Institutes of Health (NIH) grant P01 HL154996.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
Due to US Department of Veterans Affairs (VA) regulations and our ethics agreements, the analytic datasets used for this study are not permitted to leave the Million Veteran Program (MVP) research environment and VA firewall. This limitation is consistent with other MVP studies based on VA data. However, the MVP data are made available to researchers with an approved VA and MVP study protocol. The full summary level association data genome-wide association analyses in the MVP and the meta-analysis from this report will be available through dbGaP (accession number phs001672). The only restriction is that use of the data is limited to health/medical/biomedical purposes, and does not include the study of population origins or ancestry. Use of the data does include methods development research (e.g., development and testing of software or algorithms) and requestors agree to make the results of studies using the data available to the larger scientific community. We used publicly available data from GTEx (https://gtexportal.org/home/), and FinnGEN (https://www.finngen.fi/en/access_results). We utilized publicly available software for all analyses, and software used in this study is described in the Methods section.